Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.
carfilzomib
multiple myeloma
proteasome inhibitor
real world
relapsed/refractory
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
28
09
2022
revised:
29
09
2022
accepted:
29
09
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real-world data are limited. This real-world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients (
Identifiants
pubmed: 36819146
doi: 10.1002/jha2.595
pii: JHA2595
pmc: PMC9928790
doi:
Types de publication
Journal Article
Langues
eng
Pagination
174-183Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Xavier Leleu received honoraria from Amgen, BMS, CARsgen Therapeutics, Celgene, Gilead, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Roche and Takeda. Eirini Katodritou received honoraria and research funding from Amgen and Janssen‐Cilag; held membership on boards of directors or advisory committees for Amgen and Janssen‐Cilag; received expenses and research funding from Genesis Pharma and Takeda; and received research funding from AbbVie and Karyopharm Therapeutics. Thomas Kuehr received consultancy fees and honoraria from Incyte and Janssen; received honoraria and fees to cover travel, accommodation and expenses from Bayer and Lilly; and received honoraria from AbbVie, Amgen, Celgene, Merck, Novartis, Roche and Takeda. Evangelos Terpos received grants, personal fees and non‐financial support from Amgen regarding this work; received grants, personal fees and non‐financial support from Amgen, Celgene/Genesis Pharma, Janssen and Takeda; and received personal fees from AbbVie, BMS, GSK and Novartis, outside the submitted work. Jo Caers received honoraria from Amgen, Celgene, Janssen and Takeda; held membership on boards of directors or advisory committees for Amgen, Celgene, Janssen and Takeda. Renato Zambello held membership on boards of directors or advisory committees for Celgene and Janssen. Alessandra Brescianini is an employee of Amgen and an equity holder. Tony Liang is an employee of Parexel and received funding from Amgen. Sally Wetten was an employee of Amgen and an equity holder at the time of this work. Sorina N. Badelita received consultancy fees, fees to cover travel, accommodation and expenses from Amgen, Janssen and Takeda; and consultancy fees and honoraria from Novartis.
Références
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
N Engl J Med. 2008 Aug 28;359(9):906-17
pubmed: 18753647
Blood Adv. 2020 Nov 10;4(21):5449-5459
pubmed: 33166401
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
P T. 2016 May;41(5):303-7
pubmed: 27162470
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
Expert Rev Hematol. 2018 Mar;11(3):219-237
pubmed: 29415570
Expert Rev Hematol. 2014 Feb;7(1):97-111
pubmed: 24471924
Blood Cancer J. 2021 Feb 18;11(2):40
pubmed: 33602913
Blood. 2017 Aug 24;130(8):963-973
pubmed: 28679737
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Ann Hematol. 2019 Jan;98(1):1-18
pubmed: 30470875
Blood Cancer J. 2017 Apr 21;7(4):e554
pubmed: 28430175
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1-7
pubmed: 31767529
Lancet Oncol. 2021 Mar;22(3):e105-e118
pubmed: 33662288
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Haematologica. 2014 Feb;99(2):232-42
pubmed: 24497560